Comparative Pharmacology
Head-to-head clinical analysis: MYIDYL versus NATACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYIDYL versus NATACYN.
MYIDYL vs NATACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
Natamycin is a polyene antifungal that binds to ergosterol in fungal cell membranes, increasing permeability and causing cell death.
50 mg orally twice daily without regard to meals.
One drop of 5% ophthalmic suspension into the conjunctival sac every 1-2 hours for 48 hours, then taper to one drop 4-6 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
Not well characterized due to minimal systemic absorption; estimated to be 2-3 hours in plasma if absorbed.
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Primarily fecal via biliary elimination; less than 5% renal excretion of absorbed dose.
Category C
Category C
Antifungal
Antifungal, Ophthalmic